Reaction
Immune-Mediated Hepatic Disorder reporting signals
As of the last recalculation, Immune-Mediated Hepatic Disorder appears in 1,887 FAERS reports alongside 36 co-occurring drug terms. The strongest observed disproportionality signal is PEMBROLIZUMAB (PRR 232.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pembrolizumab | 1,022 | 232.6 | 234.8 |
| Ipilimumab | 399 | 129.0 | 130.2 |
| Nivolumab | 581 | 95.3 | 95.9 |
| Durvalumab | 144 | 84.4 | 85.0 |
| Axitinib | 70 | 41.1 | 41.3 |
| Pemetrexed Disodium | 126 | 39.0 | 39.1 |
| Carboplatin | 350 | 37.1 | 37.2 |
| Paclitaxel (Aibumin-Bound) | 220 | 33.3 | 33.4 |
| Paclitaxel | 239 | 30.3 | 30.4 |
| Pemetrexed | 52 | 27.5 | 27.5 |
| Magnesium Oxide | 58 | 15.7 | 15.8 |
| Atezolizumab | 53 | 15.5 | 15.5 |
| Febuxostat Tablets 40 Mg | 14 | 15.3 | 15.3 |
| Febuxostat Tablets 80 Mg | 14 | 15.3 | 15.3 |
| Lenvatinib | 43 | 14.8 | 14.8 |
| Cisplatin | 99 | 14.7 | 14.7 |
| Cabozantinib | 62 | 14.7 | 14.7 |
| Atovaquone | 10 | 13.8 | 13.8 |
| Ursosiol | 22 | 12.6 | 12.6 |
| Ursodiol | 22 | 11.3 | 11.3 |
| Dexamethasone Sodium Phosphate | 10 | 10.9 | 10.9 |
| Encorafenib | 9 | 10.1 | 10.1 |
| Gemcitabine Hydrochloride | 46 | 9.8 | 9.8 |
| Pitavastatin Calcium | 9 | 9.7 | 9.8 |
| Febuxostat | 14 | 9.3 | 9.3 |
| Fluorouracil Cream, 0.5% | 60 | 8.9 | 8.9 |
| Fluorouracil | 60 | 8.8 | 8.8 |
| Suvorexant | 9 | 7.7 | 7.7 |
| Aprepitant | 11 | 6.6 | 6.6 |
| Oxaliplatin | 43 | 6.5 | 6.5 |
| Gemcitabine | 20 | 5.6 | 5.7 |
| Icosapent Ethyl | 4 | 5.2 | 5.2 |
| Cetuximab | 14 | 5.0 | 5.0 |
| Regorafenib | 5 | 4.8 | 4.8 |
| Bevacizumab | 52 | 4.7 | 4.7 |
| Vibegron | 3 | 4.1 | 4.1 |